Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Feb;6(1):93-100.
doi: 10.21037/gs.2016.07.04.

Bisphosphonate-related osteonecrosis of jaws in advanced stage breast cancer was detected from bone scan: a case report

Prakasit Chirappapha  1 , Saowanee Kitudomrat  1 , Thanaporn Thongjood  2 , Rangsima Aroonroch  3
Affiliations
Case Reports

Bisphosphonate-related osteonecrosis of jaws in advanced stage breast cancer was detected from bone scan: a case report

Prakasit Chirappapha et al. Gland Surg. 2017 Feb.

Abstract

Bisphosphonates (BPs) are indicated to treat skeletal-related events (SREs) for cancer patients with bone metastasis. We report a 79-year-old woman with advanced stage breast cancer with bone metastasis who was prescribed BPs (zoledronate), then developed osteonecrosis of jaw. We provide a brief review of the pathogenesis, diagnosis and treatment of this complication.

Keywords: Breast cancer; bisphosphonate complication; bone metastasis; osteonecrosis of jaws.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Abnormal increased uptake at the mandible can be seen. (A) Anterior view of the bone scan; (B) posterior view of the bone scan; (C) right lateral view of the bone scan; (D) left lateral view of the bone scan. RLAT, right lateral; LLAT, left lateral.
Figure 2
Figure 2
No remarkable bone damage. (A) X-ray paronamic view of mandible; (B) X-ray periapical view of mandible.
Figure 3
Figure 3
Necrotic bone and inflammatory exudate. (A) Hematoxylin and eosin, 40×; (B) hematoxylin and eosin, 100×; (C) hematoxylin and eosin, 400×; (D) gram positive filamentous bacteria, brown and brenn stain, 400×.
See this image and copyright information in PMC

References

    1. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:1938-56. 10.1016/j.joms.2014.04.031 - DOI - PubMed
    1. Paulo S, Abrantes AM, Laranjo M, et al. Bisphosphonate-related osteonecrosis of the jaw: specificities. Oncol Rev 2014;8:254. 10.4081/oncol.2014.254 - DOI - PMC - PubMed
    1. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7. 10.1200/JCO.2005.02.8670 - DOI - PubMed
    1. Di Nisio C, Zizzari VL, Zara S, et al. RANK/RANKL/OPG signaling pathways in necrotic jaw bone from bisphosphonate-treated subjects. Eur J Histochem 2015;59:2455. 10.4081/ejh.2015.2455 - DOI - PMC - PubMed
    1. Wang EP, Kaban LB, Strewler GJ, et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007;65:1328-31. 10.1016/j.joms.2007.03.006 - DOI - PubMed

Publication types

LinkOut - more resources